Literature DB >> 1570798

Body composition in growth hormone-deficient adults.

A Binnerts1, P Deurenberg, G R Swart, J H Wilson, S W Lamberts.   

Abstract

Body composition in a group of growth hormone (GH)-deficient adults was compared with a control group matched for age, sex, body height, body weight, and body mass index by using bioelectrical impedance and deuterium oxide-dilution methods and hydrodensitometry. The body-fat percentages of GH-deficient adults were higher despite comparable weight, height, age, and body mass index. Body impedance was higher in the GH-deficient adults after correction for differences in height and fat-free mass. As a consequence, prediction formulas for body composition from body impedance developed in normal subjects cannot be applied to GH-deficient subjects. The higher body impedance in the GH-deficient subjects can be ascribed to a smaller amount of extracellular water in these subjects than in control subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570798     DOI: 10.1093/ajcn/55.5.918

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  17 in total

1.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Authors:  Tamara L Wexler; Ronen Durst; David McCarty; Michael H Picard; Lindsay Gunnell; Zehra Omer; Pouneh Fazeli; Karen K Miller; Anne Klibanski
Journal:  Growth Horm IGF Res       Date:  2010-07-03       Impact factor: 2.372

Review 3.  The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses.

Authors:  M L Vance
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

4.  Growth hormone replacement in adults.

Authors:  S M Shalet; S J Holmes
Journal:  BMJ       Date:  1994-05-21

Review 5.  Role of hormones in the pathogenesis and management of sarcopenia.

Authors:  Hosam K Kamel; Diana Maas; Edmund H Duthie
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

6.  Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group.

Authors:  Ah Reum Khang; Eu Jeong Ku; Ye An Kim; Eun Roh; Jae Hyun Bae; Tae Jung Oh; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim; Jung Hee Kim
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

7.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

8.  Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults.

Authors:  D Valle; M N D Di Minno; V Palmieri; S Pezzullo; F Cirillo; C Di Somma; G Di Minno; G Lombardi
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

9.  Body composition following hemodialysis: studies using dual-energy X-ray absorptiometry and bioelectrical impedance analysis.

Authors:  C Formica; M G Atkinson; I Nyulasi; J McKay; W Heale; E Seeman
Journal:  Osteoporos Int       Date:  1993-07       Impact factor: 4.507

10.  Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement.

Authors:  Karen K Miller; Tamara Wexler; Pouneh Fazeli; Lindsay Gunnell; Gwenda J Graham; Catherine Beauregard; Linda Hemphill; Lisa Nachtigall; Jay Loeffler; Brooke Swearingen; Beverly M K Biller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.